Product Name: 2-(2-(3-(2-(7-Chloro-2-quinolinyl)-ethenylphenyl)-3-hydroxypropyl)phenyl)-2-propanol CAS NO:142569-70-8
Chemical & Physical Properties:
Appearance : White to light yellow powder
Boiling Point:636.8℃at 760 mmHg
Montelukast can effectively inhibit the physiological effects of the binding of LTC4, LTD4 and LTE4 to the CysLT1 receptor without any receptor agonistic activity. There is a second type of cysteyl leukotriene receptor (CysLT2) in the lungs, but it may be limited to the blood vessels. So far, these two receptors have not been cloned, so the situation of CysLT receptor is mainly explained by receptor binding test and pharmacological analysis. It is now believed that montelukast sodium does not antagonize the CysLT2 receptor.
If you are interested in our products or have any questions, please feel free to contact us!
Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.